Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human single ascending dose study of intravenous ANX105 in healthy volunteers
NL-OMON53467Phase 1Active, not recruiting
- Sponsor
- Annexon Biosciences
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ANX105 in neurological diseases and autoimmune disease, sponsored by Annexon Biosciences. Primary endpoint: Safety and tolerability. Started Mar 2022; status: active, not recruiting.
02
Drugs
ANX105
03
Conditions
neurological diseasesautoimmune disease
Beyond the preview
Go deeper on NL-OMON53467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53467.